(Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date. Glaucoma affects about 2.7 million people in the United States and is the second leading cause of blindness in the world. Rhopressa helps lower the pressure due to a build up of fluid in the eye by targeting the trabecular meshwork, the main drain through which fluid flows out of the eye. For more details: New breakthrough in ophthalmology
October 1-3, 2018 | Moscow, Russia Theme: An eye on the update of ophthalmology